The Iacocca Family Foundation and Kineta Inc. Announce New Partnership on Type 1 Diabetes Mellitus Drug Development Program
SEATTLE--(BUSINESS WIRE)--Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta’s preclinical autoimmune drug candidate – ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus.